Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

Saketh S. Dinavahi, Christopher G. Bazewicz, Raghavendra Gowda, Gavin Robertson

Research output: Contribution to journalReview article

Abstract

Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.

Original languageEnglish (US)
Pages (from-to)774-789
Number of pages16
JournalTrends in Pharmacological Sciences
Volume40
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Aldehyde Dehydrogenase
Neoplasms
Therapeutics
Chemotherapy
Health Services Needs and Demand
Poisons
Radiotherapy
Protein Isoforms
Cells
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

Dinavahi, Saketh S. ; Bazewicz, Christopher G. ; Gowda, Raghavendra ; Robertson, Gavin. / Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics. In: Trends in Pharmacological Sciences. 2019 ; Vol. 40, No. 10. pp. 774-789.
@article{1cc2f85ad5ff4f8c840ca0865048c0ba,
title = "Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics",
abstract = "Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.",
author = "Dinavahi, {Saketh S.} and Bazewicz, {Christopher G.} and Raghavendra Gowda and Gavin Robertson",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.tips.2019.08.002",
language = "English (US)",
volume = "40",
pages = "774--789",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "10",

}

Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics. / Dinavahi, Saketh S.; Bazewicz, Christopher G.; Gowda, Raghavendra; Robertson, Gavin.

In: Trends in Pharmacological Sciences, Vol. 40, No. 10, 01.10.2019, p. 774-789.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics

AU - Dinavahi, Saketh S.

AU - Bazewicz, Christopher G.

AU - Gowda, Raghavendra

AU - Robertson, Gavin

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.

AB - Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85071900617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071900617&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2019.08.002

DO - 10.1016/j.tips.2019.08.002

M3 - Review article

C2 - 31515079

AN - SCOPUS:85071900617

VL - 40

SP - 774

EP - 789

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 10

ER -